Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
NCT05785208
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
122
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Osimertinib
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS